BioInsights - Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success - spotlight

CELL & GENE THERAPY INSIGHTS

Guest Editor:

Fritz Fiesser, Director, C&GT Engineering and Informatics at GlaxoSmithKline

June 2021

Cellular immuno-oncology – overcoming manufacturing and development obstacles to commercial success

Download PDF

Innovator Insight

Navigating regulations: novel cell therapy platforms and their path to clinical manufacturing

Navigating regulations: novel cell therapy platforms and their path to clinical manufacturing

N Bauer, N Calhoun, A Davies et al.

CMC obstacles in cell and gene therapy: four solutions to solve six challenges

CMC obstacles in cell and gene therapy: four solutions to solve six challenges

Subbu Viswanathan, Marc Puich

Commentary

Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy

Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy

M Bravo, T Davies, P Fairchild

Interview

Pursuing a fully closed cellular immunotherapy manufacturing model

Pursuing a fully closed cellular immunotherapy manufacturing model

Optimizing manufacturing processes to develop novel cell and gene therapies

Optimizing manufacturing processes to develop novel cell and gene therapies

Kerry Ingalls

Reflecting upon the GSK–UCL collaboration on viral vector bioprocess economics for <em>ex vivo</em> gene therapy commercialization

Reflecting upon the GSK–UCL collaboration on viral vector bioprocess economics for ex vivo gene therapy commercialization

Suzanne S Farid

A bright commercial future for off-the-shelf NK cell therapy

A bright commercial future for off-the-shelf NK cell therapy

J Spanholtz, T Jordansen, V Huppert

Viewpoint

Allogeneic T-cell therapies: from R&D lab to production facility

Allogeneic T-cell therapies: from R&D lab to production facility

Jakob Dupont, M.D., Joe Newell

Webinars

Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

Navigating regulations - novel cell therapy platforms and their path to clinical manufacturing

N Bauer, N Calhoun, A Davies et al.

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Applying a closed, modular, semi-automated system to CAR T cell therapy manufacturing

Y Ji, S PhD, N PhD

Accelerating CAR-T process development: The power of process insight

Accelerating CAR-T process development: The power of process insight

Julia Hupfeld, Ph.D.